CD274 and pancreatic neoplasm: Significantly, PKCiota could promote the immune-suppressive microenvironment in pancreatic cancer by elevating PDL1 expression, and a combination of a PDL1 inhibitor and a PKCiota inhibitor could remarkably enhance the cytotoxicity of NK92 against PDAC cells [19].